This Week in Science

A team from Brandeis University reports in Science this week on the discovery of a handful of ancient genetic mutations that are responsible for the activity of the cancer drug Gleevec against tumors expressing one type of oncogene, but not a related one. Gleevec works by blocking the activity of Abl tyrosine kinase, but is ineffective against closely homologous tyrosine kinases such as Src.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.